DDInter1938 DDInter1284
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Netupitant
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Netupitant